Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.
The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy with/without chemotherapy and no recurrence/metastasis before entry this study from five hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do risk grouping for survival analyses according to the blood test results.
Study Type
OBSERVATIONAL
Enrollment
441
Taichung Veterans General Hospital
Taichung, Taiwan
Time interval from the date of abnormal blood test to the date of clinically documented tumor relapse
From the end of treatment to any time when abnormal blood test is fund
Time frame: Five years
Overall survival (OS)
Overall survival was calculated from the day of enrollment until death or the last follow-up visit
Time frame: Five years
Event-free survival (EFS)
Event-free survival was calculated from the day of enrollment until the date of first occurrence of tumor relapse (local, regional, or distant failures) or the last follow-up visit
Time frame: Five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.